Lancet publishes phase 3 retatrutide data in type 2 diabetes

The wire

1. 01The double-blind, randomised phase 3 trial evaluated retatrutide for efficacy and safety in people with type 2 diabetes not controlled by diet and exercise alone.
2. 02Retatrutide is the most closely watched triple agonist in the incretin pipeline, and drug-naive diabetes data inform its eventual label scope.
3. 03Effect sizes, dosing arms and tolerability details are in the full publication; regulatory filings and timing were not addressed.

From the source

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial